Introduction
Introduction Statistics Contact Development Disclaimer Help
DTIC ADA485361: Lipoxygenase, Angiogenicity, and Prostate Cancer Ra...
by Defense Technical Information Center
Thumbnail
Download
Web page
Radiotherapy is a prevalent modality for the treatment of
prostate tumor. Although radiation is capable of
eradicating localized prostate tumors, nearly 30% of
patients treated with potentially curative doses relapse
at the sites of irradiation. Therefore, there is an
imperative need to improve the success rate of
radiotherapy for PCa. This proposal is focused on a role
of 12-lipoxygenase (LOX) in modulating the radiation
response of PCa cells. 12-LOX catalyzes the formation of
12(S)-hydroxyeicosatetraenoic acid (HETE). Our studies
suggest an involvement of 12-LOX in radioresistance of
PCa cells. It is our hypothesis that an increase in 12-
LOX expression/activity may lead to an increased
resistance in tumors to radiation treatment. We also
hypothesize that VEGF is an important intermediary for 12-
LOX mediated radioresistance in PCa. We intend to define
the role of 12-LOX in radioresponse in PCa. 12- LOX will
be overexpressed in LNCaP and DU145 cells. Then we will
study whether an increase in 12-LOX expression in LNCaP
and DU145 cells can enhance their resistance to
radiotherapy. We also propose to study whether VEGF is
required by 12-LOX to enhance PCa radioresistance through
blockade of VEGF activity with a neutralizing antibody.
Finally, we will evaluate whether BHPP, a 12-LOX
inhibitor, can be used to sensitize prostate tumors to
radiotherapy.
Date Published: 2018-06-24 07:07:13
Identifier: DTIC_ADA485361
Item Size: 20544650
Language: english
Media Type: texts
# Topics
DTIC Archive; Nie, Dao-Tai; SOUTHERN ...
# Collections
dticarchive
additional_collections
# Uploaded by
@chris85
# Similar Items
View similar items
PHAROS
You are viewing proxied material from tilde.pink. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.